Posted on

HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-resistant Depression (TRD), Suggesting Antidepressant Efficacy and Showing Placebo-level Dissociative Side Effects in Phase 2 Oral Prolonged-release Ketamine (KET01) Study

HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-resistant Depression (TRD), Suggesting Antidepressant Efficacy and Showing Placebo-level Dissociative Side Effects in Phase 2 Oral Prolonged-release Ketamine (KET01) Study

  • Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in efficacy.
  • Potential first-in-class oral prolonged-release formulation of ketamine, KET01, suggests larger improvement in Montgomery–Åsberg Depression Rating Scale (MADRS) scores at 15 days compared to placebo.
  • Improvement in MADRS scores shown at 7 days suggestive of rapid onset of efficacy.
  • Safety: no treatment-related serious adverse events with only placebo-level dissociative side-effects reported.

Munich, March 31, 2022 – HMNC Brain Health (“HMNC” or the “Company”), a global clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, together with Develco Pharma, a company specializing in the development and manufacture of orally administered modified, prolonged & chrono release drugs today announced promising top- line results from the Phase 2 Proof-of-Concept investigator-initiated trial of its oral prolonged- release formulation of ketamine (KET01) in Treatment-Resistant Depression (TRD).

The trial suggests a positive trend in efficacy, based on the primary endpoint clinical data: After 15 days, the highest dose of 240 mg/day KET01 was associated with a larger improvement on the Montgomery-Åsberg Depression Rating Scale (MADRS) compared with placebo (Δ=-4.99, p=0.1499). In addition, KET01 appears to be a safe and well-tolerated antidepressant, with substantially limited dissociative side effects, and scores on the Clinician-Administered Dissociative States Scale (CADSS) similar to those for placebo.

The Phase 2 trial evaluated whether KET01 administered in doses of 240 mg/day and 160 mg/day for 15 days to patients with TRD as an adjunct treatment to standard antidepressants can improve depressive symptoms compared to placebo. Recruitment stopped early after inclusion of 27 patients with TRD instead of 99, due to the effects of COVID-19 together with very stringent criteria for definition of treatment resistant depression on recruitment.

The primary endpoint, change in MADRS from baseline to day 15, showed a mean advantage of -4.99 units compared with placebo (95% confidence interval (CI): -11.81, 1.83, p=0.1499) suggesting a positive trend in efficacy for the highest tested dose (240 mg/day) on the established MADRS rating scale for depressive severity.

Additionally, the data suggest KET01 has a rapid onset of action, with a clinically meaningful improvement of -5.67 units (95%CI: -12.57, 1.23, p=0.1062) already after 7 days compared with placebo.

Importantly, safety results from the trial demonstrated that KET01 was well tolerated, with no treatment-related serious adverse events reported. The scores on the Clinician-Administered Dissociative States Scale (CADSS) were similar to those for placebo.

Dr. Hans Eriksson, HMNC Brain Health’s Chief Clinical Development Officer, said, “The encouraging preliminary results we have seen demonstrate the safety of KET01, showing the potential for development of a first-in-class, oral prolonged-release formulation of ketamine treatment for patients suffering from Treatment-Resistant Depression. In addition, our data suggest that KET01 is rapidly acting with a clinically meaningful improvement compared with placebo already after 7 days, which stands in sharp contrast to standard antidepressants which have a delayed onset of action of up to several weeks.”

The study was funded by the Ketabon program, which is a joint venture between HMNC Brain Health and Develco Pharma, sponsored by University of Zürich and conducted under the central leadership of Professor Erich Seifritz, Director of the Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich. Dr. Michael Colla coordinated the medical implementation as head of the clinical trial at the University of Zurich, as successor of Prof. Annette Brühl, after she moved to the University of Basel. The statistical evaluation of the study was carried out by SCOPE, a globally renowned CRO.

Professor Seifritz commented, “We are pleased with the top-level results from this Phase 2 study on Treatment-Resistant Depression with KET01, as they hold significant positive implications for the clinical development of oral prolonged-release ketamine to help those afflicted, making up as many as 30 percent of depression patients. Not only does the data suggest this to be a potentially safer treatment for people suffering from Major Depressive Disorder who have not found currently available antidepressants effective, but it could potentially be expanded to include additional mental-health indications in the future. Ketabon and the University of Zurich will continue to work together in the development of KET01, with future studies being planned.”

HMNC Brain Health, in partnership with Develco Pharma, is about to start a multinational, larger CRO-led Phase 2 randomized, double-blind, placebo-controlled trial in patients with TRD in the second quarter of 2022. First results are expected for mid-2023.

“We are highly encouraged by the findings in this study, showing a clinically meaningful improvement and excellent tolerability in patients treated with 240 mg/day KET01. We will bring our experiences from this study to further trials with KET01 and are looking forward to the next steps in the development of this promising medication”, said Develco Pharma CEO Dr. Martin Renner.

Dr. Eriksson added, “The suggested clinically relevant improvement in efficacy and the good safety and tolerability profile that we saw in the Phase 2 Proof-of-Concept trial support our plans for the larger study which we are preparing to launch. With the capabilities of our team and strong Scientific Advisory Board, we are well placed to undertake the next steps for progressing Ketabon towards more studies and the pathway to approval and commercialization.”

ABOUT HMNC BRAIN HEALTH

HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission rates. The Company develops a unique pipeline for targeting both Major Depressive Disorder (MDD) and Treatment- Resistant Depression (TRD). The Company has operations both in the US and Germany and is backed by a renowned global VC, several family offices, and a strategic healthcare investor. The Company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

ABOUT DEVELCO PHARMA

With headquarters in Pratteln/ Switzerland, Develco Pharma is a Swiss-German pharmaceutical company specializing in the development and manufacture of orally administered modified, prolonged & chrono release drugs containing known active ingredients. Established in 2006, today the company has a workforce of 130 employees. In Germany, a state-of-the-art production facility for analgesics & other indications has been in operation in Schopfheim, in the Baden region, since 2016. Develco identifies and defines pharmaceutical products containing known active ingredients and develops generic, hybrid, value added and innovative formulations backed by clinical data for the delayed or modified release of active ingredients. On the strength of its experience and innovativeness, the company has emerged as an internationally recognized provider of pharmaceuticals for the treatment of several disease areas. The customer base of Develco Pharma includes global pharmaceuticals groups. The company has some 180 market approvals in all (products of different dosages) in Europe, the US, Middle- East, South Africa, Asia and Australia.

ABOUT THE KETABON PROGRAM

The Ketabon program, a joint venture between HMNC Brain Health and Develco Pharma in Switzerland comprises an oral prolonged-release formulation of ketamine for TRD with minimal dissociative side effects. The pharmacokinetic profile of the prolonged-release formulation could significantly improve the risk profile and patient convenience, by minimizing dissociative side effects compared to the currently applied intravenous and intranasal ketamine therapies. TRD patients with insufficient response to standard antidepressants represent 30% of an overall estimated number of 320 million patients worldwide suffering from major depressive disorder. In this group, prolonged-release ketamine has shown high response rates. Clinical development of oral prolonged-release ketamine could also be potentially expanded into other indications, such as anxiety, aggression, PTSD, and panic disorder.

ABOUT THE PSYCHIATRIC UNIVERSITY HOSPITAL ZURICH

The Department of Psychiatry, Psychotherapy and Psychosomatics at the Psychiatric University Hospital Zurich is an internationally leading institute of translational research into innovative and novel biological and psychological treatments of psychiatric conditions, with a focus on Major Depression, Schizophrenia and Addiction. The translational approach is based on a comprehensive bio-psycho-social disease model overarching the full spectrum from molecular neuroscience to clinical and social psychiatry and back.

Media contacts

Alexander Schmidt (Europa)
+49 151 22 99 39 765
alexander.schmidt@gaulyadvisors.com

Anne Donohoe (U.S.)
+1 212-896-1265
hmnc@kcsa.com

Investor Contact (U.S.)

Tim Regan / Sophia Bashford
+1 347-487-6788
tregan@kcsa.com / sbashford@kcsa.com

Posted on

Ketamine found to be safe and effective for teen depression

Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial

One in four young adults contemplated suicide last year.

Clearly, something needs to change. Could ketamine be the solution?

A study last month found that ketamine was well-tolerated in adolescents aged 13-17 and significantly reduced their depression symptoms.

76% of participants had at least a 50% reduction in depression scores within 3 days of receiving a ketamine infusion, compared to 35% of the placebo group.

The teens had tried between 1 and 7 antidepressants without success prior to the treatment. They all remained on their medications during the trial (SSRIs, non-SSRI antidepressants, mood stabilizers, or lithium) with no serious adverse side effects.

PDF of article

Posted on

Two approaches to treating depression with DMT

Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets

After finding its DMT formulation to be well-tolerated, Small Pharma (DMT) is launching two new trials this year. 

One will assess how DMT interacts with SSRIs in patients with depression and the other will compare the drug’s effects when administered through muscles versus veins. 

The company has also developed a form of DMT that lasts longer than the typical 30 minute trip, but is still much shorter than a psilocybin or LSD trip.

Biomind Labs (BMND) is taking the opposite approach. The company reduced a DMT trip to just 10-15 minutes by making a formulation that’s inhalable.

Biomind’s formulation will be assessed in a Phase II trial for treatment-resistant depression, which just received approval by the Brazilian Institutional Review Board.

We’re eager to see if the length of the trip makes a difference!

logo light
Biomind Labs Inc.

PDF of article 1

PDF of article 2

Posted on

A better way to measure depression

MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial

Diagnosing and measuring depression is usually very subjective, relying on data from patient questionnaires. This leaves room for bias and makes it difficult to know if a treatment is actually working.

MYND Diagnostics of MYND Life Sciences (MYND) developed a biomarker test that provides objective data to solve this problem. It measures inflammation in the brain, which may be what causes depression.

Seeing evidence of improvement gives patients hope in the treatment process, like showing them the “light at the end of the tunnel” as MYND’s CEO explained on a recent Daily Mushroom Podcast.  

The company announced that Monash University will use the biomarker test in a psilocybin study on treatment-resistant depression, which has received $3M in funding from the Australian government. 

Mynd

PDF of article

Posted on

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

MYND’s Second CRA focuses on Novel Therapies for Neurological Diseases of the Brain

VANCOUVER, BC, Jan. 12, 2022 /CNW/ – MYND Life Sciences Inc.  (“MYND” or the “Company“) (CSE: MYND) (OTC: MYNDF) a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced that it has entered into Collaborative Research Agreement (the “Agreement”) with the University of British Columbia (“UBC”) focussing on Novel Therapies for Neurological Diseases.

MYND is creating safe and effective precision medicines based on proprietary technologies, targeting intractable diseases affecting the Central Nervous System, aiming to improve the standard of care for patients. This research seeks to test new compounds, including Psilocybins which may modify neurological diseases. Through 38 Health Canada licenses issued under their Section J exemptions of the Food and Drug Act issued to the UBC Laboratory, MYND possesses the enviable ability to examine the unique actions of analogues of Psilocybin. The focus is to develop, validate and patent the ability of Psilocybin-based drugs to modify outcomes in disease.

“We are very excited to announce our second Collaborative Research Agreement focussing on diseases of the brain,” stated Dr. Lyle Oberg, MYND‘s Chief Executive Officer. “We have a unique opportunity to improve the wellness and quality of life of millions of people and families torn apart by the tragedy of dementia and other debilitating diseases of the Central Nervous System. The MYND management team has a wealth of scientific, clinical and operational experience, and is well networked within the pharmaceutical industry. The Psilocybin sector is rapidly transitioning to become a pharmaceutical industry and MYND holds a unique position within the sector in terms of  building upon our unique intellectual property and a valuable portfolio of related patents”,”

The Company has a broad development pipeline, including advancing clinical programs, such as novel biomarkers for depression and MYND is expecting results from its pivotal trial to validate these biomarkers. Through its subsidiary MYND Diagnostics INC., this includes conducting an adaptive dose finding single phase 2b clinical trial funded by the Australian Government of the efficacy and safety of psilocybin assisted psychotherapy (“PAP”) in the treatment of people diagnosed with treatment resistant depression (“TRD”) in collaboration with clinical researchers at Monash University. Furthermore, MYND anticipates entering clinic trials with three additional programs in the course of 2022/2023. After progressing to clinical proof of concept, MYND will continue to have the option to enter into partnerships for late-stage development and commercialization.

“We are continuing to translate our innovative approaches, while maintaining our scientific excellence,” stated Dr. Wilfred Jefferies, Chief Science Officer at MYND. “We have unique technologies with differentiating potential and access to state-of-the-art facilities. This funding will allow us to accelerate our research dramatically leading to more rapid translation of our studies. This is a really exciting time for MYND and our team.”

DEPARTURE OF AN OFFICER OF THE COMPANY

MYND’s Chief Operating Officer, Jordan Cleland, is moving on from the company to pursue other professional opportunities effective the end of day, January 11, 2022. Cleland was MYND’s first hire in August of 2020 and provided operations set up and support in the formative months of the company. Cleland’s duties will be assumed by Dr. Chahaat Singh who will assume the role of Operations and Research Manager with MYND. Dr. Singh has a Ph.D. in Medical Genetics, a M. Sc. In Microbiology, and brings a wealth of research experience to the position.  Singh has biotech industry experience with the firms IMTech and Panacea and recently co-authored an article in the Lancet dealing with Alzheimer’s Disease. Mynd would like to thank Mr. Cleland for his dedication to the company and wishes him well in his future endeavours.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for the applications of Psilocybins for overcoming disease. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to MYND’s mailing list, please visit https://myndsciences.com/contact/.

CONTACT INFORMATION

Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

SOURCE Mynd Life Sciences Inc.

Posted on

Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin

Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin

  • Patients receive first dose in first-ever Health Canada-approved, multi-dose psilocybin clinical trial conducted at Braxia Scientific’s subsidiary CRTCE clinic
  • Trial establishes psilocybin treatment framework for patients with TRD and opens new pathway for patients to access psychedelic treatment

TORONTO, ONTARIO December 14th, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative psychedelic treatments for persons with depression and related disorders, has reached a milestone as the first Health Canada-approved multiple-dose psilocybin clinical trial which commenced with first patients dosed in November 2021. The trial, which is being sponsored by the Brain and Cognition Discovery Foundation, is being conducted at the Canadian Rapid Treatment Center of Excellence (CRTCE), a wholly owned Braxia subsidiary, and includes adults with treatment-resistant depression (TRD) as part of bipolar or unipolar disorder, who have not benefited from multiple conventional treatments. This study is the only Health-Canada approved psilocybin trial in Canada that is actively recruiting participants at this time.

Of the more than 300 million people suffering with depression worldwide, it is estimated that up to two thirds of affected people receiving treatment will inadequately respond to currently approved treatments, making patients with TRD a very large population that disproportionately dominates the majority of mental health services.

“This is a historically significant occasion for our patients, for Braxia, and for other organizations that endeavour to discover and develop innovative rapid-acting psychedelic treatments for the mental health sector,” said Braxia Scientific CEO Dr. Roger McIntyre.

“For patients who have undergone at least two – and possibly dozens of – unsuccessful conventional treatments for their depression, this remedy offers a potential and innovative treatment avenue for adults with TRD.”

“For Braxia Scientific, it marks two very important milestones. First, this trial establishes a proprietary framework and positions our platform among the leading groups that endeavour to research and develop new psychedelic treatments for TRD. Second, our proprietary data from this landmark trial will enable us to continue our work developing potential new chemical entities in the future, while providing patients with TRD immediate access to new treatment.”

Dr. Joshua Rosenblat, Braxia’s Chief Medical and Scientific Officer and the Principal Investigator (PI) of the trial, added, “Outside of rare exemptions for a very small number of patients with terminal medical illnesses, the only way to legally access psilocybin treatment in Canada is through Health Canada-approved clinical trials. As we have the country’s only open trial (e.g., only one actively recruiting, enrolling and treating participants with psilocybin), the CRTCE is currently the only place in Canada that can legally provide psilocybin for depression in the absence of any comorbid medical condition.”

Building on management’s extensive clinical and research expertise, the Company has expanded the necessary infrastructure to provide novel interventions that include ketamine, psilocybin and other potential future psychedelics that become available.

More specifically, the Company infrastructure has:

  • Established access to a high-quality source of psilocybin that meets all regulatory requirements for human use in clinical research
  • Received more than 150 referrals to date for psilocybin-assisted therapy for treatment resistant depression at our clinic in the first six weeks of opening recruitment
  • Received Health Canada and Research Ethics approval for protocols to collect treatment outcome data to allow for further optimization of psilocybin treatment protocols and development of best practice guidelines
  • Trained medical and research staff as part of Braxia Institute to provide psilocybin-assisted therapy with high quality safety monitoring. This program includes twenty (20) therapists licensed to practice in Ontario with specialized training in psilocybin-assisted therapy. All therapists were trained by the Braxia Institute and are serving as study therapists for the active psilocybin clinical trial.
  • Developed physical space to safely provide psilocybin treatment with a comfortable living room-like environment with appropriate medical and psychological monitoring and protocols

“This tremendous infrastructure enables Braxia Scientific to provide psilocybin-assisted therapy today, as part of the current clinical trial, and importantly, if psilocybin is approved in the future for use outside of clinical trials, Braxia Scientific is positioned to immediately provide access to psilocybin-assisted therapy treatment for eligible patients,” commented Dr. Rosenblat.

The trial will also provide Braxia Scientific a chance to evaluate the psilocybin-assisted therapy training program launched earlier this year. Upon completion of the psilocybin study, this program, run by the Braxia Institute, the Company’s training centre focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy, is set to graduate its first cohort of medical professionals, a multidisciplinary group of 20 therapists from diverse psychiatry and psychotherapy backgrounds.

About Braxia Scientific Corp.

Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

ON BEHALF OF THE BOARD

“Dr. Roger S. McIntyre”

Dr. Roger S. McIntyre
Chairman & CEO

FOR FURTHER INFORMATION PLEASE CONTACT:
Braxia Scientific Corp.
Tel: 416-762-2138
Email: info@braxiascientific.com
Website: www.braxiascientific.com

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement


This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are “forward-looking statements.”

Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential for ketamine to treat other emerging psychiatric disorders, such as Bipolar Depression. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the “CDSA”) and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

Posted on

The findings from COMPASS’s depression study keep coming!

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

COMPASS Pathways’ (CMPS) announced that patients taking SSRI antidepressants in conjunction with psilocybin therapy had similar outcomes and fewer side effects compared to those who withdrew from SSRIs before the study.

Five patients who withdrew from SSRIs had serious adverse effects, such as suicidal ideation, when given the largest dose. None of the patients on SSRIs had this experience. 

PDF of article

Posted on

How to cure depression in two hours

GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression

GH Research (GHRS) discovered that the most powerful psychedelic, 5-MeO-DMT (aka toad venom), is highly effective at curing treatment-resistant depression.

Out of eight patients, seven were in remission from depression just one day after receiving the company’s proprietary formulation, and five of those were in remission in as little as two hours. 

All eight patients showed improved depression scores, with an average reduction of 76%. 

GH Research Logo

PDF of article